Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to cut heart risks in psoriasis patients

NCT ID NCT05908240

Prevention Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tests whether a dedicated care coordinator can help people with psoriasis or psoriatic arthritis reduce their risk of heart disease. About 520 adults aged 40-75 who do not already take cholesterol medication will receive support to manage risk factors like high cholesterol. The goal is to prevent heart attacks and strokes by applying standard prevention methods more consistently.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 520 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to provide informed consent 2. Male or female aged 40-75 3. Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis Exclusion Criteria: 1. Currently taking a prescription lipid lowering medication 2. Pregnant or planning pregnancy in the next 6 months 3. Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis psoriatic arthritis cardiovascular disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Psoriasis Psoriatic arthritis Psoriatic conditions

Contacts and locations

Locations

  • AP Derm Clinical Research LLC

    Somerville, Massachusetts, 02145, United States

  • Bellevue Dermatology Clinic

    Bellevue, Washington, 98004, United States

  • Buffalo Medical Group

    Williamsville, New York, 14221, United States

  • Central Connecticut Dermatology Research

    Cromwell, Connecticut, 06416, United States

  • City Dermatology

    Bensalem, Pennsylvania, 19020, United States

  • Dawes Fretzin Clinical Research

    Columbus, Indiana, 47201, United States

  • Dawes Fretzin Clinical Research

    Indianapolis, Indiana, 46250, United States

  • Frontier Dermatology

    Mill Creek, Washington, 98012, United States

  • Johnson Dermatology

    Fort Smith, Arkansas, 72916, United States

  • Mayo Clinic

    Scottsdale, Arizona, 85259, United States

  • MiSkinCenter

    Northville, Michigan, 48167, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • SUNY Downstate

    Brooklyn, New York, 11203, United States

  • Southern California Dermatology

    Santa Ana, California, 92701, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of New Mexico

    Albuquerque, New Mexico, 87106, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Utah

    Salt Lake City, Utah, 84112, United States

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.